Science Daily Talks Modified Citrus Pectin

MCP Science

It seems every time we read the latest news on natural health, we see something about Modified Citrus Pectin and its unique ability to block the health-robbing protein, Galectin-3. This exciting field of research is rapidly gaining international recognition among doctors, scientists and health conscious consumers looking for natural solutions to human health issues.

On August 21st, 2012, Dr. Eliaz presented this groundbreaking body of critical data to scientists and colleagues at the 244th National Meeting and Exposition of the American Chemical Society (ACS). ACS is the world’s largest scientific organization bringing leading edge information and research breakthroughs to over 140,000 members around the world.

Read the press release featured in Science Daily here!

Your Thoughts

What do you think about this article? Please share your thoughts and experiences in the comments section below. We love to hear your feedback!

There are 4 comments for this article
  1. Judy at 11:27 am

    Per this article you say, “Eliaz said his conclusions were based on evidence from clinical trials involving close to 8,000 people.” I would like to see any links to clinical trials as I haven’t been able to find any. I did find this, ” Animal studies and a couple of uncontrolled human studies have found that MCP may inhibit the spread of prostate cancer and melanoma to other organs. However, there have been no controlled clinical studies to prove this effect in humans.”
    Thank you, Judy

  2. Leonti Thompson, M.D. at 1:03 pm

    This was an informative presentation with great implications for medical practice. I wonder if you have any specific research information concerning galectin 3 influence on diabetes 2 and chronic pain and the therapeutic effect of modified citrus pectin. Thank you.

  3. admin at 2:02 pm

    Hello Judy,

    The article was referring to the following galectin-3 PREVEND study:

    J Intern Med. 2012 Jul;272(1):55-64. doi:
    10.1111/j.1365-2796.2011.02476.x. Epub 2011 Nov 18.

    The fibrosis marker galectin-3 and outcome in the general population.

    de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van
    Gilst WH, Hillege HL,Bakker SJ, van der Harst P.

    Source

    Department of Cardiology, University Medical Center Groningen,
    University of Groningen, Groningen, The Netherlands.
    r.a.de.boer@umcg.nl

    Abstract

    OBJECTIVE:

    Galectin-3 is involved in fibrosis and inflammation and plays a role
    in heart failure, renal disease, obesity and cancer. We aimed to
    establish the relationship betweengalectin-3 and cardiovascular (CV)
    risk factors and mortality in the general population.

    DESIGN AND SUBJECTS:

    This study included 7968 subjects from the Prevention of REnal and
    Vascular ENd-stage Disease (PREVEND) cohort, with a median follow-up
    of approximately 10 years. Plasma galectin-3 was measured in baseline
    samples.

    MAIN OUTCOME MEASURES:

    We investigated the relationships between galectin-3levels,
    demographic characteristics and risk factors of CV disease. We
    determined the prognostic value for all-cause, CV and cancer
    mortality.

    RESULTS:

    The mean age of the population was 50 ± 13 years. Mean blood pressure
    was 129/74 mmHg, mean cholesterol was 5.7 ± 1.1 mmol L(-1) and median
    galectin-3 was 10.9 ng mL(-1) [interquartile range (IQR) 9.0-13.1].
    Galectin-3 levels correlated with a wide range of risk factors of CV
    disease, including blood pressure, serum lipids, body mass index,
    renal function and N-terminal pro-B-type natriuretic peptide (P < 0.0001). We observed a strong association between galectin-3 and age. Furthermore, we found a gender interaction, with female subjects (n = 4001) having higher median galectin-3 levels (11.0 ng mL(-1) , IQR 9.1-13.4 vs. men (n = 3967) 10.7 ng mL(-1) , IQR 8.9-12.8; P < 0.0001), and galectin-3 levels in women more strongly correlated with risk factors of CV disease. After correction for the classical CV risk factors (smoking, blood pressure, cholesterol and diabetes), galectin-3 levels independently predicted all-cause mortality (hazard ratio per SD galectin-3 1.09, 95% CI 1.01-1.19; P = 0.036), but not CV and cancer mortality separately. CONCLUSIONS: Galectin-3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin-3 predicts all-cause mortality in the general population. © 2011 The Association for the Publication of the Journal of Internal Medicine. Thank you for your comment! Sincerely, The Dr. Eliaz Blog Staff

  4. Lahu at 5:04 am

    I used to make excuses not to go to thpeary classes were scheduled at that time only, i had an exam to cram for, etc. What I find unfortunate about thpeary and psychiatry is that if someone has a chronic mental health problem, like I have, and I need to go to thpeary weekly and nutrition appointments, I can\’t get out of work during business hours, when most practitioners have office hours. Some work places most work places are non-negotiable about missing an hour every week for a doctor\’s appointment. While many private practitioners have evening or sometimes Saturday hours, most group practices are open during business hours, when people who could benefit from appointments, can\’t get away from work. I understand your point about making time for appointments and assignments, and I definitely appreciate you writing about it.